CIBC Asset Management Inc Has $26.02 Million Stock Holdings in Bristol Myers Squibb Company $BMY

CIBC Asset Management Inc raised its stake in Bristol Myers Squibb Company (NYSE:BMY) by 68.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 482,466 shares of the biopharmaceutical company’s stock after buying an additional 196,274 shares during the quarter. CIBC Asset Management Inc’s holdings in Bristol Myers Squibb were worth $26,024,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BMY. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb in the 2nd quarter valued at $25,000. Physician Wealth Advisors Inc. raised its holdings in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares in the last quarter. EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb in the 4th quarter valued at $32,000. KERR FINANCIAL PLANNING Corp acquired a new position in Bristol Myers Squibb in the 3rd quarter valued at $35,000. Finally, Garner Asset Management Corp acquired a new position in Bristol Myers Squibb in the 4th quarter valued at $35,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BMY has been the subject of several analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. HSBC lifted their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a report on Tuesday, March 17th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Bank of America decreased their price target on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $61.31.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Trading Up 0.8%

Shares of BMY opened at $54.89 on Thursday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The business’s fifty day moving average is $58.15 and its 200-day moving average is $56.45. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The firm has a market cap of $112.09 billion, a price-to-earnings ratio of 15.42, a PEG ratio of 0.16 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Jefferies reiterated its Buy rating on Bristol Myers Squibb, which supports the stock’s valuation case and may be helping sentiment. Jefferies Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
• Positive Sentiment: Bristol Myers said Opdivo received an EU label expansion for use with AVD in newly diagnosed advanced classical Hodgkin lymphoma, a commercial win that could lift future oncology revenue. BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos
• Positive Sentiment: Arcus Biosciences announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate casdatifan in kidney cancer, adding another pipeline-related catalyst. Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan…

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.